QR Code

Eligibility for vericiguat in a real‐world, contemporary heart failure population

Abstract Aims Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real‐world data on how many patients could be eligible for vericiguat therapy derive from ou...

Description complète

Enregistré dans:
Auteurs principaux: Giuseppe Vergaro, Alberto Aimo, Francesco Gentile, Giulia Elena Mandoli, Marta Focardi, Vincenzo Castiglione, Alberto Giannoni, Giorgia Panichella, Alessandra Fornaro, Erberto Carluccio, Riccardo Liga, Mattia Salatin, Claudio Passino, Massimo F. Piepoli, Matteo Cameli, Francesco Cappelli, Carlo Di Mario, Michele Emdin
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2024-12-01
Collection:ESC Heart Failure
Sujets:
Vericiguat
Heart failure
Therapy
Guidelines
Population
Accès en ligne:https://doi.org/10.1002/ehf2.14767
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires